Search

Kymera Therapeutics Inc

Закрыт

СекторЗдравоохранение

121.25 -0.05

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

117.71

Макс.

122.06

Ключевые показатели

By Trading Economics

Доход

8M

-61M

Продажи

31M

65M

Прибыль на акцию

-0.62

Рентабельность продаж

-94.171

Сотрудники

273

EBITDA

6M

-61M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+8.17% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.7B

10B

Предыдущая цена открытия

121.3

Предыдущая цена закрытия

121.25

Новостные настроения

By Acuity

50%

50%

156 / 340 Рейтинг в Healthcare

Kymera Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 авг. 2026 г., 19:26 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier decline. No specific news was identified to explain the movement.

17 авг. 2026 г., 19:54 UTC

Kymera Therapeutics Inc shares are trading higher today amid increased volume, maintaining a positive trend since Friday's close despite earlier intraday fluctuations.

14 авг. 2026 г., 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12 авг. 2026 г., 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6 авг. 2026 г., 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5 авг. 2026 г., 20:02 UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4 авг. 2026 г., 20:04 UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3 авг. 2026 г., 19:46 UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31 июл. 2026 г., 20:06 UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30 июл. 2026 г., 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29 июл. 2026 г., 19:32 UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28 июл. 2026 г., 17:42 UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27 июл. 2026 г., 21:03 UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24 июл. 2026 г., 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 июл. 2026 г., 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 июл. 2026 г., 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Сравнение c конкурентами

Изменение цены

Kymera Therapeutics Inc Прогноз

Целевая цена

By TipRanks

8.17% рост

Прогноз на 12 месяцев

Средняя 131.33 USD  8.17%

Максимум 155 USD

Минимум 112 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Kymera Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

18 ratings

16

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

156 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat